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The detection of the JAK2V617F mutation has become an
essential tool in BCR-ABL1-negative myeloproliferative neoplasms
(MPNs) diagnosis, as it is present in 95% of polycythemia vera (PV)
patients and 60% of essential thrombocytemia (ET) or myelo-
ﬁbrosis patients.
1 JAK2V617F-positive MPNs are different from
other hematological malignant disease in that, although the
JAK2V617F mutation is considered as the causative origin of the
disease, the tumor burden at the time of diagnosis as assessed by
the % of JAK2V617F alleles in peripheral blood or bone marrow
can vary from 100% to very low levels with no correlation to blood
cell counts. It is still undeﬁned which lowest level might be
detected to allow the diagnosis of every MPN patients. Using the
Mustascreen kit (Ipsogen, Marseilles, France), the detection limit of
which was close to 2%, most of the patients were easily classiﬁed
as positive or negative. However, some rare patients were
considered as doubtful because the level of ﬂuorescence
detected from the mutant probe was between the negative
control and the 2% reference positive kit control. Recently, we
decided to move toward a more sensitive method, the Mutaquant
kit (Ipsogen), characterized by a detection limit close to 0.1%. DNA
was extracted from whole blood using the QIA-AMP DNA blood
mini kit (Qiagen, Hilden, Germany). In the few months after we
adopted a more sensitive method, we identiﬁed positive patients
among patients previously tested negative. These results raised
two questions: who are the patients with very low levels of
JAK2V617F mutation and consequently what level of sensitivity a
method should have in a routine diagnosis setting. All patients
included have given informed consent for this study, which has
been approved by the local ethics committee.
To assess the speciﬁcity of the Mutaquant method, 49 samples
taken from blood donors were tested and no sample was detected
as positive using a cut-off of 0.1%. Next, we diluted one 100%
mutated patient DNA sample in a negative one. The 10
2 and
10
3 dilutions were measured at 1.2% and 0.1%, respectively,
whereas the 10
4 dilution was found negative. These results
conﬁrmed the lower detection limit of this method to be 0.1%
mutant allele burden.
Within 6 months after introducing Mutaquant in a routine
setting, we prospectively investigated 688 patients. Overall, 497
were tested for the ﬁrst time, whereas 191 had already been
analyzed previously using Mutascreen method. In 98 cases, the
previous sample was positive and the Mutaquant result conﬁrmed
the positivity. In 93 cases, the previous result was negative, but in
7 of them the Mutaquant method detected a low level of
JAK2V617F mutant allele (Table 1). When reanalyzed using the
novel method, a low level of positivity was also detected on a
frozen aliquot of the previous sample for these seven patients. In
three cases several DNA samples were available, which were all
found positive with Mutaquant, even samples taken as far as 5
years before, with a constant level of positivity throughout time.
Of these seven patients, three were suspected of having ET, one
presented with an isolated elevated hematocrit and one with a
myeloﬁbrosis. Patient 6 presented with a high WBC count, normal
Table 1. Biological and clinical data of seven patients found positive, although repeatedly tested negative previously
Patient Age
(years)
Sex Date of
sampling
Mutaquant
(%)
Mutascreen Diagnosis Cytoreductive
treatment
HTC
(%)
Hb
(g/dl)
WBC
(G/l)
PLT
(G/l)
Additional
mutations
#1 49 F 2008 0.30 Neg NA NA NA 720 MPL neg
2009 0.50 Neg ET HU
2011 0.60 ND
#2 49 M 2007 0.90 Neg 47.4 17.1 7.7 335 MPL neg
2011 0.70 ND Thrombosis None
#3 47 M 2006 1.00 Neg 42 12.9 5.6 600 MPL neg
2010 1.00 Neg ET None
2011 0.90 ND
#4 49 M 2010 0.10 Neg None 54 18.1 7.5 189 Exon 12 neg
2011 0.20 ND PV
#5 56 F 2007 0.20 Neg 39.5 12.8 6.5 340 MPL neg
2010 0.20 Neg ET HU
2011 0.20 ND
#6 72 F 2010 0.60 Neg 42.3 14.6 13.4 134 MPL neg
2011 0.50 ND MPN None
#7 71 F 2010 0.20 Neg 30.5 10.4 5.9 100 MPL neg
2011 0.30 ND Myeloﬁbrosis None
Abbreviations: ET, essential thrombocytemia; Exon 12, mutation at the exon 12 of the JAK2 gene; F, female; HTC, hematocrit; HU, hydroxyurea; M, male; MPL,
mutation at W515 of the MPL gene; NA, not available; ND, not done; Neg, negative; PLT, platelet; Pos, positive; PV, polycythemia vera.
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www.nature.com/bcjRBC and platelet counts, circulating immature myeloid cells and
trisomy 8 in bone marrow cells. A chronic neutrophilic leukemia, a
rare entity in which JAK2V617F has been reported,
2 is unlikely in
this case because of immature circulating myeloid cells and the
absence of splenomegaly or segmented neutrophils. Patient 7
presented with unexplained repeated pulmonary embolisms
without any hematological abnormality and a red cell mass in
the normal range, excluding a polycythemia. The impact of the
mutation in this patient is still questioning as JAK2V617F in
thrombotic syndromes is frequent in splanchnic vein thrombosis
3,
but extremely rare in unprovoked thrombosis.
4 We analyzed DNA
from erythroid colonies from patient 3 and, in line with the DNA
from total blood (1%), we found one JAK2V617F heterozygous
colony among 48 tested, conﬁrming the existence of a very low
mutant allele burden.
An unsolved question is whether a mutant allele burden of 1%
or less really reﬂects the tumor burden and whether the patients
found with less than 1% of JAK2V617F allele burden can be
classiﬁed as MPN patients, as the WHO classiﬁcation do not
require quantitative analysis.
5 In ET, a restriction of the mutation to
the megakaryocytic lineage could lead to underestimation of the
mutated cells percentage when analyzing blood DNA. Platelet
RNA may be a better material to evaluate the tumor allele burden
in some cases. We excluded the presence of an additional
mutation in MPL (MPL Mutascreen kit) or the exon 12 of JAK2 (as
previously described
6) as driving the phenotype for every patient
with less than 1% allele burden. Some studies reported the
presence of extremely low levels (o0.1%) of JAK2V617F in healthy
people,
7,8 which may be explained in two ways: either the
mutation can be transient or the mutant allele burden can rise
from undetectable to detectable levels throughout time and those
patients are in a preclinical phase. Among the seven patients
identiﬁed in our study with low allele burden, ﬁve were suspected
of MPN because of increased hematocrit or platelet counts or
myeloﬁbrosis. The JAK2 mutation conﬁrmed the clonal myelo-
proliferation and allowed to ascertain the diagnosis of MPN.
We next reanalyzed frozen aliquots from 18 patients declared
doubtful with Mutascreen. Using Mutaquant we detected
JAK2V617F mutation in eight patients (Table 2), with an allele
burden close to 2%. Suspected diagnosis at the time of sampling
was myeloﬁbrosis, ET and PV in 1, 2 and 5 patients, respec-
tively. Only patient 25 was questionable as he presented with
subnormal hematocrit throughout time, but his son had a
JAK2V617F-positive PV.
As a conclusion, our study argues for the choice of a JAK2V617F
detection method characterized by a detection limit under 1% in
order to identify more MPN patients. However, using such a
method will inevitably lead to the detection of patients with very
low allele burden, the diagnosis of which may be questionable,
although according to the WHO classiﬁcation the detection of the
JAK2V617F mutation is one of the major criteria leading to MPN
diagnosis,
5 with no indication regarding the allele burden. Careful
examination of patient’s phenotype is needed before modifying
treatment strategy until a large cohort of such patients will allow
to decipher upon their outcome.
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Table 2. Biological and clinical data of eight patients found with detectable JAK2V617F mutations, although previously tested doubtful
Patient Age (years) Sex Suspected diagnosis % JAK2V617F Vascular events Treatment HTC (%) Hb (g/dl) WBC (G/l) PLT (G/l)
#10 81 F Myeloﬁbrosis 4.8 No None 27.7 9.0 9.5 24
#11 84 M PV 1.3 No None 55 18.5 8.7 217
#14 61 M PV 1.3 No Phlebotomy 48 16.2 9.9 221
#16 78 F PV 2.9 No ASA, HU 60 18.3 12.1 490
#19 63 F PV 2.6 No None 50.3 17 11.3 197
#23 65 M ET 2.8 Yes ASA, HU 33.5 10.4 10.6 1200
#24 25 F ET 1.1 Yes ASA, HU 36.3 12.8 4.8 238
#25 64 M PV 1.5 No ASA 46.4 16.2 6.5 247
Abbreviations: ASA, aspirin; ET, essential thrombocytemia; HTC, hematocrit; HU, hydroxyurea; NA, not available; PLT, platelet; PV, polycythemia vera. Only data
from patients with detectable are presented. In patients with low allele burden of JAK2V617F mutation, JAK2 exon 12 mutations have been tested in patients
with PV, whereas MPL515 mutations have been tested in patients with either ET or myeloﬁbrosis
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